NEW INDICATIONS

Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors

JHOP - October 2021 Vol 11, No 5 - FDA Oncology Update
Download PDF

On August 17, 2021, the FDA accelerated the approval of dostarlimab-gxly (Jemperli; GlaxoSmithKline) for adults with mismatch repair-deficient (dMMR), as determined by an FDA-approved test, recurrent or advanced solid tumors that progressed during or after treatment for whom there are no satisfactory alternative options.

On the same day, the FDA also approved the VENTANA MMR RxDx Panel as a companion diagnostic test to select appropriate candidates for dostarlimab therapy. Dostarlimab was initially approved in April 2021 for endometrial cancer.

The FDA approval of dostarlimab for this indication was based on the GARNET study, a nonrandomized, multicenter, open-label, multicohort clinical trial of 209 patients with dMMR recurrent or advanced solid tumors that progressed after systemic therapy.

The primary end points were overall response rate (ORR) and duration of response (DOR). The ORR was 41.6%, including 9.1% complete responses and 32.5% partial responses. The median DOR was 34.7 months; 95.4% of the patients had a response lasting ≥6 months.

The most common (≥2%) grade 3 or 4 adverse events were anemia, fatigue/asthenia, increased transaminases, sepsis, and acute kidney injury. Immune-mediated adverse reactions associated with dostarlimab include pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic toxicity.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: